新辅助内分泌治疗与新辅助化疗治疗激素受体阳性/人表皮生长因子受体2阴性乳腺癌的疗效比较  

Comparison the efficacy of neoadjuvant endocrine therapy and neoadjuvant chemotherapy for hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer

作　　者：倪健彬 王颖 吴祥虎 NI Jianbin;WANG Ying;WU Xianghu(Department of Surgical Oncology,Xinyang Central Hospital,Xinyang 464000,He’nan,China;Department of Gynaecology and Obstetrics,Xinyang Central Hospital,Xinyang 464000,He’nan,China)

机构地区：[1]信阳市中心医院肿瘤外科,河南信阳464000 [2]信阳市中心医院妇产科,河南信阳464000

出　　处：《癌症进展》2024年第1期96-99,共4页Oncology Progress

基　　金：河南省科技攻关计划项目(192102310065)。

摘　　要：目的比较新辅助内分泌治疗与新辅助化疗治疗激素受体(HR)阳性(+)/人表皮生长因子受体2(HER2)阴性(-)乳腺癌的疗效。方法依据治疗方法的不同将110例HR+/HER2-乳腺癌患者分为对照组和观察组,每组55例,对照组患者给予新辅助化疗,观察组患者给予新辅助内分泌治疗,两组均于治疗后择期行手术治疗。比较两组患者的临床疗效、肿瘤标志物[糖类抗原125(CA125)、糖类抗原15-3(CA15-3)]水平、Ki-67表达情况、预后不良风险[术前内分泌预后指数(PEPI)]和不良反应发生情况。结果观察组患者的治疗总有效率为85.45%,高于对照组患者的69.09%,差异有统计学意义(P﹤0.05)。治疗后,观察组患者Ki-67高表达率低于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者血清CA125、CA15-3水平均低于本组治疗前,观察组患者血清CA125、CA15-3水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者预后不良高风险发生率为12.73%,低于对照组患者的32.73%,不良反应总发生率为7.27%,低于对照组患者的36.36%,差异均有统计学意义(P﹤0.05)。结论新辅助内分泌治疗HR+/HER2-乳腺癌患者的疗效和预后均优于新辅助化疗,可抑制Ki-67的表达,降低肿瘤标志物水平,安全性较高。Objective To compare the efficacy of neoadjuvant endocrine therapy and neoadjuvant chemotherapy for hormone receptor(HR)positive(+)/human epidermal growth factor receptor 2(HER2)negative(-)breast cancer.Method According to different treatment methods,110 HR+/HER2-breast cancer patients were divided into control group and observation group,with 55 cases in each group.The patients in the control group were received neoadjuvant chemotherapy,while the patients in the observation group were received neoadjuvant endocrine therapy.The clinical efficacy,tumor markers[carbohydrate antigen 125(CA125),carbohydrate antigen 15-3(CA15-3)]levels,Ki-67 expression,risk of poor prognosis[preoperative endocrine prognostic index(PEPI)],and incidence of adverse reactions were compared between two groups.Result The total effective rate of the observation group was 85.45%,which was higher than 69.09%in the control group,and the difference was statistically significant(P<0.05).After treatment,the high expression rate of Ki-67 in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum CA125 and CA15-3 in both groups were lower than those before the treatment,the levels of serum CA125 and CA15-3 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of high-risk poor prognosis in the observation group was 12.73%,which was lower than 32.73%in the control group,and the total incidence of adverse reactions was 7.27%,which was lower than 36.36%in the control group,and the differences were statistically significant(P<0.05).Conclusion The efficacy and prognosis of neoadjuvant endocrine therapy for HR+/HER2-breast cancer patients are better than neoadjuvant chemotherapy,which can inhibit the expression of Ki-67,reduce tumor marker levels,and have higher safety.

关 键 词：乳腺癌 激素受体 人表皮生长因子受体2 新辅助内分泌治疗 新辅助化疗 临床疗效 

分 类 号：R737.9[医药卫生—肿瘤]